Stephens Investment Management Group LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.5% in the 3rd quarter, Holdings Channel reports. The fund owned 1,413,040 shares of the biopharmaceutical company’s stock after buying an additional 20,221 shares during the quarter. Halozyme Therapeutics accounts for about 1.7% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 4th biggest position. Stephens Investment Management Group LLC’s holdings in Halozyme Therapeutics were worth $156,000,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Bank of America Corp DE purchased a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $214,504,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics during the second quarter valued at approximately $196,540,000. Jupiter Topco LLC bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth about $105,570,000. Caisse de depot et placement du Quebec bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $83,940,000. Finally, Congress Asset Management Co. increased its position in shares of Halozyme Therapeutics by 85.6% during the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts recently issued reports on HALO shares. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 11th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $105.00 to $109.00 in a research note on Wednesday, November 11th. Stifel Nicolaus set a $130.00 target price on shares of Halozyme Therapeutics in a research note on Friday, October 16th. HC Wainwright raised their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $108.18.
View Our Latest Report on Halozyme Therapeutics
Halozyme Therapeutics Stock Performance
Shares of NASDAQ:HALO opened at $95.80 on Thursday. The business has a 50-day moving average of $113.81 and a two-hundred day moving average of $85.87. The firm has a market capitalization of $10.92 billion, a PE ratio of 24.38, a P/E/G ratio of 0.36 and a beta of 0.92. The company has a debt-to-equity ratio of 13.50, a current ratio of 3.88 and a quick ratio of 3.60. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $134.00.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The business had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same quarter last year, the firm earned $1.72 earnings per share. The company’s revenue for the quarter was up 39.1% compared to the same quarter last year. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current year.
Insider Activity at Halozyme Therapeutics
In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $75,534,196.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $96.43, for a total value of $482,150.00. Following the completion of the transaction, the director directly owned 48,609 shares in the company, valued at $4,687,365.87. This represents a 9.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 149,226 shares of company stock worth $15,744,643. Company insiders own 2.50% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
